Merck announced Wednesday that the FDA OK’d RECARBIO, a combination of imipenem, cilastatin and relebactam in a 1.25g injection formulation.
The drug is intended to treat patients 18 and older for complicated urinary tract infection, or cUTI — including pyelonephritis — caused by some susceptible gram-negative microorganisms and for which there is limited or no alternative treatment options.
The antibacterial medication is also indicated to treat complicated intra-abdominal infections.
“RECARBRIO offers an additional treatment option for patients with cIAI and cUTI who have limited and, in some cases, no alternative therapeutic options,” Keith Kaye, a principal investigator of the clinical program that evaluated the antibiotic combo, said in a statement.
Merck shares were trading higher by 0.42% at $81.93 at the time of publication Wednesday.
(C) 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.